Press releases
Stayble Therapeutics publishes year-end report for 2024
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2024. The report is available as an attached document and on the...
Stayble provides update on partnership activities
Stayble Therapeutics AB ("Stayble" or "the Company") today provides an update on the ongoing work to establish partnerships for the pain treatment STA363. The Company...
(SV) – Stayble Therapeutics AB (publ) offentliggör utfallet av utnyttjande av teckningsoptioner av serie TO2
EJ FÖRPUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA,...
Abstract on the effect of STA363 on disc volume from the phase 1b study has been accepted for oral presentation at a major international congress
Stayble Therapeutics AB ("Stayble" or "the Company") announces that its scientific abstract on the effect of STA363 on disc volume reduction in patients with lumbar...
Interview with US payer expert on the US market and STA363´s potential
Stayble Therapeutics AB ("Stayble" or "the Company") has interviewed Rachelle, a US Payer Expert about her view on the US market, challenges in the market...
Interview with Jane Buus Laursen – an experienced pharma dealmaker and Board member of Stayble
Stayble Therapeutics AB ("Stayble" or "the Company") has interviewed Jane Buus Laursen about her view from an experienced dealmaker's perspective on STA363 and our coming...
Stayble accelerates partnering process with the support of advisors
Stayble Therapeutics AB ("Stayble" or "the Company") today announces the intensification of its partnering activities with the company’s drug candidate STA363 in collaboration with a...
Stayble’s CEO, Andreas Gerward, presented (in Swedish) at Financial Stockholm on December 11, 2024
Stayble Therapeutics AB ("Stayble" or "the Company") CEO, Andreas Gerward, presented (in Swedish) the Company, the results from phase 1b, and the path forward at...
Stayble Therapeutics reports additional data strengthening the STA363 treatment for pain caused by disc herniation
Stayble Therapeutics AB ("Stayble" or the "Company") has previously announced positive results from the Company's clinical phase 1b study in lumbar disc herniation (LDH). The...
Stayble Therapeutics publishes interim report for the third quarter of 2024
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its interim report for the third quarter of 2024. The report is available as an attached...
Stayble Therapeutics publishes year-end report for 2024
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2024. The report is available as an attached document and on the...
(SV) – Stayble Therapeutics AB (publ) offentliggör utfallet av utnyttjande av teckningsoptioner av serie TO2
EJ FÖRPUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA,...
Stayble Therapeutics publishes interim report for the third quarter of 2024
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its interim report for the third quarter of 2024. The report is available as an attached...